dorfmanmaster

Gilead in tested channel

Long
NASDAQ:GILD   Gilead Sciences, Inc.
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.

Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.

A close below the 50sma would change the sentiment, and remove us from the channel.

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.